WMA
CDTX

West Michigan Advisors’s Cidara Therapeutics CDTX Stock Holding History

West Michigan Advisors’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,500
Closed -$1.58M – 277
2025
Q3 		$1.58M Hold
16,500
– – 0.38% 76
2025
Q2 		$804K Buy
16,500
+3,000
+22% +$72.1K 0.23% 85
2025
Q1 		$291K Buy
+13,500
New +$300K 0.1% 155
2024
Q2 		– Sell
-6,750
Closed -$124K – 181
2024
Q1 		$124K Buy
+6,750
New +$96.9K 0.04% 175

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

West Michigan Advisors's CDTX Position: Q4 2025 in Review

West Michigan Advisors sold out of Cidara Therapeutics (CDTX) in Q4 2025, closing a stake of 16,500 shares — an estimated $1.58M sold.

West Michigan Advisors first reported a position in CDTX in Q1 2024 and held it in 4 quarters. The position peaked at $1.58M in Q3 2025. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

  • West Michigan Advisors reported no remaining Cidara Therapeutics position as of Q4 2025 after selling out during the quarter.
  • West Michigan Advisors sold 16,500 Cidara Therapeutics shares in Q4 2025, an estimated $1.58M.
  • West Michigan Advisors first reported a position in Cidara Therapeutics in Q1 2024 and held it in 4 quarters.
  • West Michigan Advisors's Cidara Therapeutics position peaked at $1.58M in Q3 2025.
  • 255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on West Michigan Advisors's 13F filing for Q4 2025, filed 28 Jan 2026.